Tissue Factor Expression in Obese Type 2 Diabetic Subjects and Its Regulation by Antidiabetic Agents

Figure 3

Plasma TF activity at baseline and following treatment with metformin ((a), (b), and (e)) and rosiglitazone ((c), (d), (e)). The -axis numbers (1–8) in Figure 3(b) and (1–10) in Figure 3(d) represent each patient and are not identical as these are subjects from two treatments studies. For metformin-treated subjects in panels (a), (b), and (e): N = 8 ± SD. For rosiglitazone-treated subjects in panels (c), (d), and (e): N = 10 ± SD. , baseline versus rosiglitazone. Baseline clinical characteristics of subjects are indicated in Table 1(b).

(a)

(b)

(c)

(d)

(e)